Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription
Cecilia Patitucci, … , Mario Pende, Ganna Panasyuk
Cecilia Patitucci, … , Mario Pende, Ganna Panasyuk
Published April 10, 2017
Citation Information: J Clin Invest. 2017;127(5):1873-1888. https://doi.org/10.1172/JCI90327.
View: Text | PDF
Research Article Hepatology Oncology

Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription

  • Text
  • PDF
Abstract

Worldwide epidemics of metabolic diseases, including liver steatosis, are associated with an increased frequency of malignancies, showing the highest positive correlation for liver cancer. The heterogeneity of liver cancer represents a clinical challenge. In liver, the transcription factor PPARγ promotes metabolic adaptations of lipogenesis and aerobic glycolysis under the control of Akt2 activity, but the role of PPARγ in liver tumorigenesis is unknown. Here we have combined preclinical mouse models of liver cancer and genetic studies of a human liver biopsy atlas with the aim of identifying putative therapeutic targets in the context of liver steatosis and cancer. We have revealed a protumoral interaction of Akt2 signaling with hepatocyte nuclear factor 1α (HNF1α) and PPARγ, transcription factors that are master regulators of hepatocyte and adipocyte differentiation, respectively. Akt2 phosphorylates and inhibits HNF1α, thus relieving the suppression of hepatic PPARγ expression and promoting tumorigenesis. Finally, we observed that pharmacological inhibition of PPARγ is therapeutically effective in a preclinical murine model of steatosis-associated liver cancer. Taken together, our studies in humans and mice reveal that Akt2 controls hepatic tumorigenesis through crosstalk between HNF1α and PPARγ.

Authors

Cecilia Patitucci, Gabrielle Couchy, Alessia Bagattin, Tatiana Cañeque, Aurélien de Reyniès, Jean-Yves Scoazec, Raphaël Rodriguez, Marco Pontoglio, Jessica Zucman-Rossi, Mario Pende, Ganna Panasyuk

×

Figure 4

HNF1α is a novel negative regulator of PPARG gene transcription.

Options: View larger image (or click on image) Download as PowerPoint
HNF1α is a novel negative regulator of PPARG gene transcription.
(A) Loc...
(A) Localization of putative HREs in the human PPARG gene. Gray and white rectangles represent noncoding and coding exons, respectively. Black rectangles represent putative HREs. Arrows mark localization of the PPARG isoform–specific promoters. (B) Relative enrichment of endogenous HNF1α at putative HREs on the PPARG and ALB genes in unsynchronized HUH7 cells. Data are means ± SEM, n = 3 independent experiments. *P < 0.05 vs. IgG; 2-tailed, unpaired Student’s t test. (C) The luciferase reporter activity normalized to β-gal activity in primary hepatocytes overexpressing HNF1α or GFP using HNF4A or PPARG promoter constructs. Data are presented as fold difference over empty vector–transfected AdGFP-infected condition. Data are means ± SEM, n = 3 independent hepatocyte cultures. *P < 0.05 vs. empty vector; 1-way ANOVA with Tukey’s multiple-comparisons test. (D) Immunoblot analysis of PPARγ protein after HNF1α overexpression in primary hepatocytes 24 hours after transduction with increasing doses of adenoviruses (0.5, 1, and 5 MOI). Immunoblot with anti-GAPDH antibody served as a loading control. (E) Luciferase activity of FGB-LUC, normalized to Renilla, measured in livers of 2-month-old male mice sacrificed 24 hours after hydrodynamic shock delivery. Data are means ± SEM, n = 3–7. *P < 0.05 vs. WT; #P < 0.05 vs. Pten LKO; 2-tailed, unpaired Student’s t test. (F and G) Immunoblot analysis of total protein extracts (F) and relative transcript levels (G) of HNF1α and HNF1α target genes in liver tissue of 4-month-old random-fed male mice. Densitometric analysis of actin-normalized signals is presented as a graph. Data are means ± SEM, n = 4–5. *P < 0.05 vs. WT; #P < 0.05 vs. Pten LKO mice; 2-tailed, unpaired Student’s t test.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts